Clinical trials in cancer prevention: Current results and perspectives for the future

Journal of Nutrition

Volumn 134, Issue 12 SUPPL., 2004, Pages

  Greenwald, Peter ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; Cancer; Clinical trials; Prevention; Prostate cancer

Indexed keywords

3 INDOLEMETHANOL; ALPHA TOCOPHEROL; ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; CELECOXIB; DOXERCALCIFEROL; FINASTERIDE; ISOFLAVONE; LYCOPENE; PERILLYL ALCOHOL; PHYTOESTROGEN; POLYPHENOL; RALOXIFENE; RETINOID; RETINOL; SELENIUM; SELENOMETHIONINE; SOYBEAN PROTEIN; STEROID 5ALPHA REDUCTASE INHIBITOR; SULFORAPHANE; TAMOXIFEN;

BREAST CANCER; CANCER PREVENTION; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; LIFESTYLE; NUTRITION; PROSTATE CANCER; RISK FACTOR;

GLYCINE MAX;

EID: 9744264033     PISSN: 00223166     EISSN: None     Source Type: Journal    
DOI: 10.1093/jn/134.12.3507s     Document Type: Conference Paper

References (46)

1. Greenwald, P. (2002) Cancer prevention clinical trials. J. Clin. Oncol. 20: 14S-22S.
2. Doll, R. & Peto, R. (1981) The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J. Natl. Cancer Inst. 66: 1191-1308.
3. Calle, E. E., Rodriguez, C., Walker-Thurmond, K. & Thun, M. J. (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 348: 1625-1638.
4. Negri, E., La Vecchia, C. L., Franceschi, S., D'Avanzo, B. & Parazzini, F. (1991) Vegetable and fruit consumption and cancer risk. Int. J. Cancer 48: 350-354.
5. Chemoprevention Working Group., Alberts, D. S., Colvin, O. M., Conney, A. H., Ernster, V. L., Garber, J. E., Greenwald, P., Gudas, L. J., Hong, W. K., et al. (1999) Prevention of cancer in the next millennium: report of the chemoprevention working group to the American Association for Cancer Research. Cancer Res. 59: 4743-4758.
6. Pentel, P. & Malin, D. (2002) A vaccine for nicotine dependence: targeting the drug rather than the brain. Respiration 69: 193-197.
7. Stillman, F., Hartman, A., Graubard, B., Gilpin, E., Chavis, D., Garcia, J., Wun, L.-M., Lynn, W. & Manley, M. (1999) The American Stop Smoking Intervention Study. Conceptual framework and evaluation design. Eval. Rev. 23: 259-280.
8. Greenlee, R. T., Murray, T., Bolden, S. & Wingo, P. A. (2000) Cancer Statistics, 2000. CA Cancer J. Clin. 50: 7-33.
9. Newman, L. A., Wood, W. C., Sellin, R. V., Morrow, M., Vogel, C. & Singletary, S. E. (2000) Symposium overview: estrogens and antiestrogens in managing the patient with breast cancer. Ann. Surg. Oncol. 7: 568-574.
10. Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90: 1371-1388.
11. Dunn, B. K., Kramer, B. S. & Ford, L. G. (1998) Phase III, large-scale chemoprevention trials. Approach to chemoprevention clinical trials and phase III clinical trial of tamoxifen as a chemopreventive for breast cancer-the US National Cancer Institute experience. Hematol. Oncol. Clin. North Am. 12: 1019-1036.
12. Cummings, S. R., Eckert, S., Krueger, K. A., Grady, D., Powles, T. J., Cauley, J. A., Norton, L., Nickelsen, T., Bjarnason, N. H., et al. (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. J. Am. Med. Assoc. 281: 2189-2197.
13. Grese, T. A., Sluka, J. P., Bryant, H. U., Cullinan, G. J., Glasebrook, A. L., Jones, C. D., Matsumoto, K., Palkowitz, A. D., Sato, M., Termine, J. D., Winter, M. A., Yang, N. N. & Dodge, J. A. (1997) Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc. Natl. Acad. Sci. U.S.A. 94: 14105-14110.
14. Vogel, V. G., Costantino, J. P., Wickerham, D. L., Cronin, W. M. & Wolmark, N. (2002) The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial. Clin. Breast Cancer 3: 153-159.
15. Jordan, V. C., Osipo, C., Schafer, J. M., Fox, J. E., Cheng, D. & Liu, H. (2003) Changing role of the oestrogen receptor in the life and death of breast cancer cells. Breast 12: 432-441.
16. Anthony, M., Dunn, B. K. & Sherman, S., editors (2001) Selective Estrogen Receptor Modulators, vol. 949. Ann. N.Y. Acad. Med. New York, NY.
17. Fabian, C. J. (2001) Breast cancer chemoprevention: beyond tamoxifen. Breast Cancer Res. 3: 99-103.
18. Mokbel, K. (2002) The evolving role of aromatase inhibitors in breast cancer. Int. J. Clin. Oncol. 7: 279-283.
19. Aapro, M. S. & Forbes, J. F. (2003) Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate. Breast Cancer Res. Treat. 80 (suppl. 1):S3-11.
20. World Cancer Research Fund (1997) Food, Nutrition and the Prevention of Cancer: A Global Perspective. American Institute for Cancer Research, Washington, DC.
21. Kelloff, G. J., Crowell, J. A., Hawk, E. T., Steele, V. E., Lubet, R. A., Boone, C. W., Covey, J. M., Doody, L. A., Omenn, G. S., et al. (1996) Clinical development plans for cancer chemopreventive agents: indole-3-carbinol. J. Cell. Biochem. 265 (suppl. 26S): 127-136.
22. Osborne, M. P. (1999) Chemoprevention of breast cancer. Surg. Clin. North Am. 79: 1207-1221.
23. Duffy, C. & Cyr, M. (2003) Phytoestrogens: potential benefits and implications for breast cancer survivors. J. Womens Health (Larchmt.) 12: 617-631.
24. Wang, C. & Kurzer, M. S. (1998) Effects of phytoestrogens on DNA synthesis in MCF-7 cells in the presence of estradiol or growth factors. Nutr. Cancer 31: 90-100.
25. Toma, S., Isnardi, L., Raffo, P., Dastoli, G., De Francisci, E., Riccardi, L., Palumbo, R. & Bollag, W. (1997) Effects of all-trans-retinoic acid and 13-cisretinoic acid on breast cancer cell lines: growth inhibition and apoptosis induction. Int. J. Cancer 70: 619-627.
26. Camacho, L. H. (2003) Clinical applications of retinoids in cancer medicine. J. Biol. Regul. Homeost. Agents 17: 98-114.
27. Weir, H. K., Thun, M. J., Hankey, B. F., Ries, L. A., Howe, H. L., Wingo, P. A., Jemal, A., Ward, E., Anderson, R. N. & Edwards, B. K. (2003) Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J. Natl. Cancer Inst. 95: 1276-1299.
28. Brawley, O. W., Knopf, K. & Thompson, I. (1998) The epidemiology of prostate cancer part II: the risk factors. Semin. Urol. Oncol. 16: 193-201.
29. Brawley, O. W., Ford, L. G., Thompson, I., Perlman, J. A. & Kramer, B. S. (1994) 5-Alpha-reductase inhibition and prostate cancer prevention. Cancer Epidemiol. Biomarkers Prev. 3: 177-182.
30. Feigl, P., Blumenstein, B., Thompson, I., Crowley, J., Wolf, M., Kramer, B. S., Coltman, C. A., Jr., Brawley, O. W. & Ford, L. G. (1995) Design of the Prostate Cancer Prevention Trial (PCPT). Control. Clin. Trials. 16: 150-163.
31. Thompson, I. M., Goodman, P. J., Tangen, C. M., Lucia, M. S., Miller, G. J., Ford, L. G., Lieber, M. M., Cespedes, R. D., Atkins, J. N., et al. (2003) The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349: 215-224.
32. Meydani, M. (1995) Vitamin E. Lancet. 345: 170-175.
33. Heinonen, O. P., Albanes, D., Virtamo, J., Taylor, P. R., Huttunen, J. K., Hartman, A. M., Haapakoski, J., Malila, N., Rautalahti, M., et al. (1998) Prostate cancer and supplementation with α-tocopherol and β-carotene: incidence and mortality in a controlled trial. J. Natl. Cancer. Inst. 90: 440-446.
34. Chan, J. M., Stampfer, M. J., Ma, J., Rimm, E. B., Willett, W. C. & Giovannucci, E. L. (1999) Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol. Biomarkers Prev. 8: 893-899.
35. Clark, L. C., Dalkin, B., Krongrad, A., Combs, G. F., Jr., Turnbull, B. W., Slate, E. H., Witherington, R., Herlong, J. H., Janosko, E., et al. (1998) Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br. J. Urol. 81: 730-734.
36. Klein, E. A., Thompson, I. M., Lippman, S. M., Goodman, P. J., Albanes, D., Taylor, P. R. & Coltman, C. (2001) SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. J. Urol. 166: 1311-1315.
37. The SELECT Prostate Cancer Prevention Trial [Online]. National Cancer Institute, http://www.nci.nih.gov/select [accessed July 17, 2004].
38. Hoque, A., Albanes, D., Lippman, S. M., Spitz, M. R., Taylor, P. R., Klein, E. A., Thompson, I. M., Goodman, P., Stanford, J. L., et al. (2001) Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes Control 12: 627-633.
39. Kaluzny, A. D., Warnecke, R. B., Lacey, L. M., Morrissey, J. P., Gillings, D. & Ozer, H. (1993) Cancer prevention and control within the National Cancer Institute's Clinical Trials Network: lessons from the Community Clinical Oncology Program. J. Natl. Cancer. Inst. 85: 1807-1811.
40. Giovannucci, E., Rimm, E. B., Liu, Y., Stampfer, M. J. & Willett, W. C. (2002) A prospective study of tomato products, lycopene, and prostate cancer risk. J. Natl. Cancer Inst. 94: 391-398.
41. Kucuk, O., Sarkar, F. H., Sakr, W., Djuric, Z., Pollak, M. N., Khachik, F., Li, Y.-W., Banerjee, M., Grignon, D., et al. (2001) Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol. Biomarkers Prev. 10: 861-868.
42. Parnes, H. L., House, M. G., Kagan, J., Kausal, D. J. & Lieberman, R. (2004) Prostate cancer chemoprevention agent development: the National Cancer Institute, Division of Cancer Prevention portfolio. J. Urol. 171: S68-S74.
43. Steele, V. E. (2003) Current mechanistic approaches to the chemoprevention of cancer. J. Biochem. Mol. Biol. 36: 78-81.
44. Verma, M. & Srivastava, S. (2003) New cancer biomarkers deriving from NCI early detection research. Recent Results Cancer Res. 163: 72-84.
45. Yip, T. T. & Lomas, L. (2002) SELDI ProteinChip array in oncoproteomic research. Technol. Cancer Res. Treat. 1: 273-280.
46. Ye, S. Q., Usher, D. C. & Zhang, L. Q. (2002) Gene expression profiling of human diseases by serial analysis of gene expression. J. Biomed. Sci. 9: 384-394.